secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alamar Biosciences, Inc. (ALMR)
CIK:        0002104204
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001193125-26-213379
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alamar Q1 revenue doubled to $26.0M; net loss $21.3M on convertible note remeasurement
--------------------------------------------------------------------------------

- Total revenue $26.0M, +99% YoY; consumable revenue surged 178% to $14.0M.
- Gross margin improved to 56% from 49% on manufacturing efficiencies and product mix.
- Net loss $21.3M, including $8.6M non-cash loss on convertible notes; operating loss $12.3M.
- Cash $69.5M at March 31; after quarter-end IPO raised $197.8M net proceeds.
- Launched NULISAseq Neuro 220 Panel and NULISAqpcr AD 5-plex in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2104204/000119312526213379/0001193125-26-213379-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2104204/000119312526213379/ck0002104204-20260508.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-213379

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer